Abstract:A series of new 2,4‐dichloro‐6‐methylpyrimidine derivatives were designed and synthesized as potential epidermal growth factor receptor (EGFR)T790M/L858R inhibitors for the treatment of non‐small cell lung cancer (NSCLC), among which L‐18 was the most promising antitumor compound. Many patients with non‐small cell lung cancer (NSCLC) initially benefit from epidermal growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance or side effects eventually develop. Overcoming and preventing the resistance and side effects of EGFR inhibitors has become a hot topic of research today. Based on the previous studies on AZD‐9291, we designed and synthesized two series of 2,4‐dichloro‐6‐methylpyrimidine derivatives, 19 compounds in total, as potential inhibitors of the EGFR kinase. The most promising compound, L‐18, showed better inhibitory activity (81.9%) and selectivity against EGFRT790M/L858R kinase. In addition, L‐18 showed strong antiproliferative activity against H1975 cells with an IC50 value of 0.65 ± 0.06 μM and no toxicity to normal cells (LO‐2). L‐18 was able to dose‐dependently induce the apoptosis of H1975 cells and produced a cell‐cycle‐blocking effect, and it can also dose‐dependently inhibit the migration and invasion of H1975 cells. L‐18 also showed in vivo anticancer efficacy in H1975 cells xenograft mice. We also performed a series of in vivo and in vitro toxicological evaluations of compound L‐18, which did not cause obvious injury in mice during administration. These results suggest that L‐18 may be a promising drug candidate that warrants further investigation.

Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Discovery of 4,6-Pyrimidinediamine Derivatives As Novel Dual EGFR/FGFR Inhibitors Aimed EGFR/FGFR1-positive NSCLC.

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Discovery, Design and Synthesis of 6H-Anthra[1,9-cd]isoxazol-6-one Scaffold As G9a Inhibitor Through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification

Discovery of New Lenalidomide Derivatives As Potent and Selective GSPT1 Degraders.

Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies

5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma

Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (hdacs): Discovery of Novel Multitargeting Antitumor Agents

Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors As a Promising Strategy for Cancer Therapy.

Novel Dual-Targeting Inhibitors of NSD2 and HDAC2 for the Treatment of Liver Cancer: Structure-Based Virtual Screening, Molecular Dynamics Simulation, and in Vitro and in Vivo Biological Activity Evaluations

Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell lung cancer

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer